Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of CYP2C9 and OATP1B1 polymorphisms on nateglinide metabolism
ChiCTR-ONC-11001810Phase 4Completed
- Sponsor
- Pharmacogenetics Research Institute, Xiangya Hospital, Central South University
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nateglinide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Pharmacogenetics Research Institute, Xiangya Hospital, Central South University. Primary endpoints: Plasma concentration of nateglinide and Plasma glucose concentration. Started Apr 2007; status: completed.
02
Drugs
nateglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-ONC-11001810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-11001810.